Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: position statement of the German allergy societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA) by Klimek, Ludger et al.
position article
Allergo J Int (2021) 30:51–55
https://doi.org/10.1007/s40629-020-00160-4
Severe allergic reactions after COVID-19 vaccinationwith
the Pfizer/BioNTech vaccine in Great Britain and USA
Position statement of the German Allergy Societies: Medical Association of
German Allergologists (AeDA), German Society for Allergology and Clinical
Immunology (DGAKI) and Society for Pediatric Allergology and Environmental
Medicine (GPA)
Ludger Klimek · Natalija Novak · Eckard Hamelmann · Thomas Werfel · Martin Wagenmann · Christian Taube ·
Andrea Bauer · Hans Merk · Uta Rabe · Kirsten Jung · Wolfgang Schlenter · Johannes Ring · Adam Chaker ·
Wolfgang Wehrmann · Sven Becker · Norbert Mülleneisen · Katja Nemat · Wolfgang Czech · Holger Wrede ·
Randolf Brehler · Thomas Fuchs · Thilo Jakob · Tobias Ankermann · Sebastian M. Schmidt · Michael Gerstlauer ·
Christian Vogelberg · Thomas Zuberbier · Karin Hartmann · Margitta Worm
Accepted: 17 December 2020 / Published online: 24 February 2021
© The Author(s) 2021
Summary Two employees of the National Health Ser-
vice (NHS) in England developed severe allergic reac-
tions following administration of BNT162b2 vaccine
against COVID-19 (coronavirus disease 2019). The
British SmPC for the BNT162b2 vaccine already in-
cludes reference to a contraindication for use in indi-
viduals who have had an allergic reaction to the vac-
cine or any of its components. As a precautionary
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measure, the Medicines and Healthcare products Reg-
ulatory Agency (MHRA) has issued interim guidance
to the NHS not to vaccinate in principle in “patients
with severe allergies”. Allergic reactions to vaccines
are very rare, but vaccine components are known to
cause allergic reactions. BNT162b2 is a vaccine based
on an mRNA embedded in lipid nanoparticles and
blended with other substances to enable its transport
A. Bauer
Clinic and Polyclinic for Dermatology, University Allergy
Center, University Clinic Carl Gustav Carus, Technical
University Dresden, Dresden, Germany
H. Merk
Department of Dermatology and Allergology, RWTH
Aachen, Aachen, Germany
U. Rabe
Clinic for Allergology, Johanniter Hospital in Fläming
Treuenbrietzen GmbH, Treuenbrietzen, Germany
K. Jung
Practice for Dermatology, Immunology and Allergology,
Erfurt, Germany
W. Schlenter
Medical Association of German Allergologists, Dreieich,
Germany
J. Ring
Skin and Laser Center at the Opera, Munich, Germany
K Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and. . . 51
position article
into the cells. In the pivotal phase III clinical trial,
the BNT162b2 vaccine was generally well tolerated,
but this large clinical trial, used to support vaccine
approval by the MHRA and US Food and Drug Ad-
ministration, excluded individuals with a “history of
a severe adverse reaction related to the vaccine and/or
a severe allergic reaction (e.g., anaphylaxis) to a com-
ponent of the study medication”. Vaccines are recog-
nized as one of the most effective public health in-
terventions. This repeated administration of a foreign
protein (antigen) necessitates a careful allergological
history before each application and diagnostic clarifi-
cation and a risk–benefit assessment before each in-
jection. Severe allergic reactions to vaccines are rare
but can be life-threatening, and it is prudent to raise
awareness of this hazard among vaccination teams
and to take adequate precautions while more expe-
rience is gained with this new vaccine.
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Background
On December 9, 2020, the Medicines and Healthcare
products Regulatory Agency (MHRA) in the United
Kingdom informed of severe allergic reactions in two
employees of the National Health Service (NHS) in
England following administration of BNT162b2 vac-
cine against COVID-19 (Coronavirus disease 2019).
Both patients had a history of anaphylaxis, and as
far as is currently known both recovered rapidly and
completely from these severe allergic reactions. Since
it is not clear which component of the vaccine trig-
gered the reaction, an investigation was initiated to
fully understand the two incidents and their causes.
The British summary of product characteristics
(SmPC) for the BNT162b2 vaccine already includes
reference to a contraindication for use in individu-
als who have had an allergic reaction to the vaccine
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or any of its components [1]. As a precautionary
measure, the MHRA has issued interim guidance to
the NHS not to vaccinate in principle “patients with
severe allergies”. It is likely that the restriction on
indications now imposed by the MHRA will result in
significantly fewer patients being able to receive the
vaccine.
Further adverse reaction reports can be expected
from the U.S. Food and Drug Administration’s (FDA)
Emergency Use Authorization (EUA) for BNT162b2
granted on December 11, 2020, as very large vaccina-
tion numbers are now likely to be achieved rapidly.
Allergic reactions to vaccines
Allergic reactions to vaccines are very rare, occurring
at 1 per 1,000,000 to 30 per 100,000 vaccinations [2–6].
Vaccine components known to cause allergic reac-
tions include residues of animal proteins, antimicro-
bial agents, preservatives, stabilizers, and adjuvants
in addition to the active component of the vaccine
(the actual antigen) that elicit the immune response
[2–6]. Individual vaccine components associated with
causing vaccine anaphylaxis include chicken egg pro-
tein, gelatin, cow’s milk proteins, and other additives
and trace compounds left over from the manufactur-
ing process, in addition to latex components from the
sealing plugs in multiple vaccine vials [3–6].
The vaccine BNT162b2
BNT162b2 is “temporarily licensed” in the United
Kingdom for active immunization to prevent COVID-
19 disease caused by the SARS-CoV-2 virus in persons
16 years of age and older [7].
The vaccine is administered intramuscularly in two
doses of 0.3ml each, 21 days apart. Thawed COVID-19
mRNA vaccine BNT162b2 requires dilution in its orig-
inal vial (0.45ml) with 1.8ml of unpreserved sodium
chloride 0.9% solution for injection, prior to with-
drawing a 0.3ml dose [7, 8].
The listed excipients in BNT162b2 are ALC-0315
((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-
hexyl decanoate), ALC-0159 (2-((polyethylene glycol)-
2000)-N,N-ditetradecylacetamide), 1,2-distearoyl-sn-
glycero-3-phosphocholine, cholesterol, potassium
chloride, potassium dihydrogen phosphate, sodium
chloride, disodium hydrogen phosphate dihydrate,
sucrose, and water for injection [7, 8].
One vial (0.45ml) contains five doses of 30µg of
highly purified, single-stranded, 5′-capped mRNA
(BNT162b2 RNA) produced by cell-free in vitro tran-
scription on an appropriate DNA template and en-
coding the viral spike(S) protein of SARS-CoV-2 [7,
8].
This mRNA is embedded in lipid nanoparticles.
mRNA is rapidly degraded by ribonucleases, readily
taken up by mononuclear phagocytes, and has poor
ability to penetrate cell membranes due to its negative
electrical charge and high molecular weight. There-
fore, mRNA requires a protective envelope for use
as a vaccine. In the BioNTech vaccine, lipid-based
nanoparticles (LNPs) are used as nonviral vectors
for this purpose, containing cationic lipids that coat
the polyanionic mRNA with its tertiary or quaternary
amines, complemented by zwitterionic lipids that
mimic cell membrane phospholipids, and cholesterol
that stabilizes the lipid bilayer of the nanoparticle.
Finally, polyethylene glycol (PEG)-modified lipids en-
able the assembly of a hydrate shell, increasing the
solubility of the LNPs.
PEG or macrogol is a polyether compound com-
monly used as an additive in cosmetics, pharmaceu-
ticals, and also in foods [9]. PEG exists in molecular
weight types ranging from 200g/mol to
10,000,000g/mol and allergic reactions have been
reported after its use in a variety of drugs and cos-
metic products [10, 11]. There is cross-reactivity to
polysorbate 80 due to common chemical motifs [12,
13]. Allergic reactions to PEG are probably diag-
nosed too rarely, so PEG is also considered a “hidden”
allergen [11]. Severe allergic reactions have been de-
scribed in diagnostic skin testing, so this should only
be performed in allergy-specialized centers according
to published standard regimens.
In the pivotal phase III clinical trial, the BNT162b2
vaccine was generally well tolerated [8]. A total
of 43,548 participants were randomized, of whom
43,448 received one injection, 21,720 with BNT162b2
and 21,728 with placebo 18,556 received a second
dose of BNT162b2 [8]. The most common adverse
reactions were local reactions at the injection site
(84.7%), fatigue (62.8%), headache (55.1%), muscle
pain (38.3%), chills (31.9%), joint pain (23.6%), fever
(14.2%) [7, 8]. Most reactions were mild to moderate
in severity. Severe adverse reactions occurred in up
to 4.6% and were more common after the second
dose and less common in adults >55 years of age.
Lymphadenopathy was reported in 0.3%. Systemic
adverse reactions were usually mild or moderate in
severity, generally occurring the day after vaccination
and lasting one to two days thereafter [7, 8]. The
occurrence of allergic reaction was reported in simi-
lar numbers in both the vaccine-verum and placebo
groups (0.63% vs. 0.51%) [7, 8]. However, this large
clinical trial, used to support vaccine approval by the
MHRA and FDA, excluded individuals with a “history
of a severe adverse reaction related to the vaccine
and/or a severe allergic reaction (e.g., anaphylaxis) to
a component of the study medication” [7, 8]. Based
on this the UK package insert based on this states that
the vaccine should not be administered to individuals
who are allergic to the active ingredient or any of the
other ingredients listed. In this respect, the patient
information complies with the exclusion criteria of
the clinical trial.
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Evaluation and outlook
Vaccines are recognized as one of the most effective
public health interventions. The primary goal of vac-
cination programs is the protection of the vaccinated
individuals. In addition, in many cases they also aim
to protect unvaccinated individuals. The ultimate goal
is creating herd immunity, i.e., resistance to the spread
of a contagious disease in a population, which occurs
when a sufficiently high proportion of individuals are
immune to that disease, especially through vaccina-
tion [14].
The development of such herd immunity requires
vaccination rates of >60% of the total population [14].
However, to achieve effective individual immuniza-
tion of >95% with BNT162b2, a second vaccination
(“booster”) is necessary. This repeated administration
of a foreign protein (antigen) necessitates a careful al-
lergological history before each application and diag-
nostic clarification, if necessary, and risk–benefit as-
sessment before each injection.
Against this background we state that
 Patients and peoplewho are to receive a vaccination
against COVID-19 must also be regularly informed
about possible severe allergic/anaphylactic reac-
tions and questioned with regard to such incidents
in the past.
 Allergic reactions to additives, in particular PEG and
cross-reactive PEG analogues, must be systemati-
cally queried in order to identify patients at risk.
 In suspected cases, allergological clarification (skin
prick test, laboratory diagnostics) and consultation
of an allergist should be carried out.
 Personnel performing vaccination against COVID-
19 must always be prepared for the possibility of
severe allergic/anaphylactic reactions and vacci-
nation teams and vaccination centers should be
trained in the treatment of anaphylaxis according to
the recommendations of the current AWMF guide-
line on the acute therapy and management of ana-
phylaxis [15].
 It will be important to understand the specific cause
of the two reported severe allergic reactions and the
medical history of the individuals involved so that
any risks of allergic reactions can bemore accurately
defined and, if possible, circumvented.
 Current authority guidelines in the UK exclude pa-
tients with severe allergies from vaccination with
BNT162b2.
 More precise definitions of the type, cause, and
severity of severe allergic reactions are needed be-
cause, given the high incidence of patients with
“severe” allergies (a significant proportion of the
total population in Europe and the US, depend-
ing on the definition), excluding all such patients
from vaccination could have a significant impact
on achieving the goal of herd immunity. On the
other hand, a more precise definition (e.g., “ana-
phylaxis-prone patients”) would suggest only 1–3%
of the population for whom vaccination would be
impossible or only possible with special protective
measures.
 More data need to be collected from both clini-
cal trials and clinical practice that will improve
our knowledge of the safety profile of COVID-19
vaccines, particularly with regard to severe allergic
reactions.
Severe allergic reactions to vaccines are rare but can
be life-threatening, and it is prudent to raise aware-
ness of this hazard among vaccination teams and to
take adequate precautions while more experience is
gained with this new vaccine. Patients with a history
of severe allergic reactions may be vaccinated with
adequate medication and by physicians experienced
in the management of anaphylactic reactions if the
ongoing investigation in the UK allows this recom-
mendation. PEG is currently considered to have most
likely triggered the severe allergic reactions in the 2 af-
fected patients in the UK, but further investigations
are awaited.
If confirmed, it would only be necessary to exclude
patients with known allergic reactions to PEG, PEG
analogs, and other additives from vaccination with
BNT162b2, but not all patients with a history of se-
vere allergic reactions, which would significantly ex-
pand the pool of potentially vaccinatable individuals.
For BNT162b2, safety monitoring will continue for
2 years after administration of the second vaccine
dose within the study [8].
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